10.02.2021
"C-reactive protein triggers cell death in ischemic cells":
In the Research Topic "Diagnostic and Therapeutic Applications of Pentraxin and Pentraxin-Associated Proteins" of the journal Frontiers in Immunology, a review on the pathomechanism of CRP in organ-damaging inflammation was published.
25.01.2021
The page 'Healthcare in Europe' reported about the recently successfully treated COVID-19 patient.
20.01.2021
The Märkische Oderzeitung reported about a recently successfully treated COVID-19 patient. The patient was treated 4 times with CRP apheresis and is recovering rapidly from the disease. The article describes that the therapy most likely saved the patient from intensive care medical treatment.
13.01.2021
The use of CRP apheresis in COVID-19 patients was presented once again in the rbb PRAXIS magazine.
The feature reports the recent successful treatment of a COVID-19 patient with apheresis. In addition, Prof. Dr. Kielstein from the Braunschweig Clinic advocates for the therapy.
Dezember 2020
Here is a “short” teaser to record our webinar on anti-inflammatory strategies for COVID-19, which is intended to provide an overview of what we believe to be the most exciting topics, key messages and areas of conflict at the event.
14.12.2020
Pentracor GmbH recently held its first webinar with renowned physicians from Germany and Switzerland to discuss the increasingly clear relevance of the pathological function of CRP in the inflammatory, severe phase of COVID-19.
03.12.2020
To meet the strict hygiene requirements for emergency overnight stays, the Berliner Stadtmission has an increasing need for Corona rapid tests for guests and staff.
01.12.2020
The Märkische Oder Zeitung reported about Pentracor GmbH and CRP apheresis as a therapy option for Covid-19 patients. The article briefly describes the company's history with all the challenges overcome so far as well as the possibility to help Corona patients.
18.11.2020
He was awarded in the category 'Medical Innovation Practices & Clinics - Cardiology' for the application of the innovative CRP apheresis after myocardial infarction. He prevailed against almost all colleagues, in particular also from university hospitals and heart centers.
14.10.2020
Der 100. Patient wurde dieser Tage mit der CRP-Apherese behandelt. Diese Behandlung lief im Rahmen der CABY1-Studie (CRP-Apherese nach koronarer Bypass-Operation) und wurde wie gewohnt sicher durchgeführt. Wir freuen uns, dass nun schon 100 Patienten von der Therapie profitieren konnten und hoffen, noch zahlreichen weiteren Menschen helfen zu können.
